A Phase I Study of Repeated Neural Stem Cell Based Virotherapy in Combination With N-Acetylcysteine Amid (NACA) and Standard Radiation and Chemotherapy for Newly Diagnosed High Grade Glioma

The goal of this clinical trial is to learn about the safety and feasibility of administering repeated doses of neural stem cell (NSC)-conditionally replicative adenovirus (CRAd)-survivin (S)-protomer (p)k7, in persons with newly diagnosed high grade glioma.
The main questions it aims to answer are:
* whether multiple doses of NSC-CRAd-S-pk7 are safe and feasible
* how multiple doses of NSC-CRAd-S-pk7 influence tumor response, overall survival, time to tumor progression, and quality of life.
Participants will:
* undergo a biopsy to confirm high grade glioma, then receive the first dose of NSC-CRAd-S-pk7 into the brain
* about 2 weeks later, undergo surgery to remove the tumor and receive the second dose of NSC-CRAd-S-pk7 into the brain
* start chemoradiation about 2 weeks after surgery, then about 2 weeks later, receive the 3rd dose of NSC-CRAd-S-pk7 into the brain
* four weeks later, at the end of chemoradiation, receive a fourth dose of NSC-CRAd-S-pk7 into the brain.
* after radiation is finished, receive standard of care chemotherapy and tumor-treating fields. Two additional doses of NSC-CRAd-S-pk7 will be given every 4 weeks.
Every other patient enrolled will receive N-acetylcysteine amide (NACA), from registration until the day prior to surgery and the second dose of NSC-CRAd-S-pk7.

Start Date15 Apr 2025

Sponsor / Collaborator

Northwestern University

NCT05994534

/ RecruitingPhase 1/2

A Phase 1/2 Pharmacokinetic and Pharmacodynamic Study of NPI-001 Oral Solution Compared to Cysteamine Bitartrate in Cystinosis Patients

Safety, pharmacokinetics, and pharmacodynamics of NPI-001 oral solution in cystinosis patients compared with cysteamine.

Start Date29 Oct 2023

Sponsor / Collaborator

Nacuity Pharmaceuticals, Inc.

IRCT20231017059756N1

/ RecruitingPhase 3IIT

Investigating the therapeutic effect of statin relative to the N-acetyl cysteine in the treatment of Helicobacter pylori patients

Start Date23 Oct 2023

Sponsor / Collaborator

Mashhad University of Medical Sciences

100 Clinical Results associated with N-Acetylcysteine amide

100 Translational Medicine associated with N-Acetylcysteine amide

100 Patents (Medical) associated with N-Acetylcysteine amide

293

Literatures (Medical) associated with N-Acetylcysteine amide

01 Mar 2025·TALANTA

Rational engineering of ligands & metal nodes: MOF-on-MOF based probe for efficient integration of anti-interference and triple signal amplification

Article

Author: Wang, Jiaqing ; Ma, Zhanfang ; Han, Hongliang

Accurate and sensitive detection of slight fluctuations in insulin concentration is essential for the assessment and treatment of early diabetes. The requirement posed a serious challenge to the responsiveness of electrochemical sensors in analyzing slight fluctuation in concentration and their ability to accurately identify the target analyte. Therefore, a MOF-on-MOF (NH₂-MIL-88B-on-NH₂-UiO-66) probe with integrated anti-interference and signal-amplification capabilities was designed by engineering functionalized ligands and metal nodes, which ensures the sensitivity of sensors while improving the detection accuracy. Signal-amplification: the bimetallic ion nodes of MOF-on-MOF act synergistically at the sensing interface (sodium citrate doped poly-thionine/poly (3, 4-ethylenedioxythiophene) film) to impede the electron transfer, leading to a decrease in the poly-thionine (PThi) oxidation current signal. The complexed Fe³⁺ triggers a Fenton reaction, further leading to a decrease in the PThi oxidation current signal. A triple amplification of the PThi oxidation current signal response induced by changes in concentration per unit of analyte was achieved. Anti-interference: The growth of a more hydrophilic MOF on the surface of another less hydrophilic MOF and the introduction of a large number of amino groups resulted in a significant anti-interference property of the MOF-on-MOF based immunoprobes. The proposed sensor not only achieves detection limits of insulin at the fg level, but also has a signal response per unit change in insulin concentration being 5-50 times higher than existing electrochemical sensors. The integration of the hydrophilic and triple signal amplification strategy is significant in the monitoring of slight fluctuations of analyte concentrations.

01 Mar 2025·Journal of Pharmaceutical Analysis

Strategy for cysteine-targeting covalent inhibitors screening using in-house database based LC-MS/MS and drug repurposing

Article

Author: Li, Na ; Wu, Jian-Lin ; Hu, Xiaolan ; He, Quan ; Xiong, Zhi-Qi

Targeted covalent inhibitors, primarily targeting cysteine residues, have attracted great attention as potential drug candidates due to good potency and prolonged duration of action. However, their discovery is challenging. In this research, a database-assisted liquid chromatography-tandem mass spectrometry (LC-MS/MS) strategy was developed to quickly discover potential cysteine-targeting compounds. First, compounds with potential reactive groups were selected and incubated with N-acetyl-cysteine in microsomes. And the precursor ions of possible cysteine-adducts were predicted based on covalent binding mechanisms to establish in-house database. Second, substrate-independent product ions produced from N-acetyl-cysteine moiety were selected. Third, multiple reaction monitoring scan was conducted to achieve sensitive screening for cysteine-targeting compounds. This strategy showed broad applicability, and covalent compounds with diverse structures were screened out, offering structural resources for covalent inhibitors development. Moreover, the screened compounds, norketamine and hydroxynorketamine, could modify synaptic transmission-related proteins in vivo, indicating their potential as covalent inhibitors. This experimental-based screening strategy provides a quick and reliable guidance for the design and discovery of covalent inhibitors.

01 Mar 2025·AMERICAN JOURNAL OF VETERINARY RESEARCH

Oxidative stress induces plasma membrane phosphatidylserine externalization in canine erythrocytes in vitro, mitigated by thiol antioxidants

Article

Author: Santos, Andrea Pires dos ; Woolcock, Andrew D. ; Moore, George E. ; Kao, Yun-Fan ; Serpa, Priscila B. S.

Abstract:

OBJECTIVE:

To determine if oxidative stress induces phosphatidylserine (PS) externalization in canine erythrocytes and if exposure to antioxidants prevents such changes.

METHODS:

This was an in vitro, experimental study using 5 healthy, adult, purpose-bred research Beagles. Fresh EDTA-anticoagulated blood samples were collected from each dog, and erythrocytes were harvested. For objective 1, erythrocytes were exposed to the pro-oxidant agents tert-butyl hydroperoxide (TBHP) at 2, 3, or 4 mM or 2,2′-azobis(2-amidinopropane) dihydrochloride at 30, 40, or 50 mM. For objective 2, erythrocytes were exposed to 3 mM TBHP and the antioxidant N-acetylcysteine-amide (NACA) at various concentrations (0, 1, or 3 mM). Erythrocytes incubated with benzoylbenzoyl-ATP were used as positive control, whereas erythrocytes incubated with sodium chloride medium with 0.1% bovine serum albumin, DMSO, and NACA were used as negative controls. Erythrocytes were stained with allophycocyanin-conjugated Annexin V, and PS externalization was assessed by flow cytometry. The degree of PS externalization of each sample was recorded as median fluorescence intensity and percentage of PS positivity.

RESULTS:

TBHP at 3 and 4 mM caused increased PS externalization in canine erythrocytes. 2,2′-Azobis(2-amidinopropane) dihydrochloride at all concentrations caused increased PS externalization. N-acetylcysteine-amide at all concentrations prevented significant PS externalization measured by median fluorescence intensity and percentage of PS positivity from erythrocytes exposed to TBHP.

CONCLUSIONS:

Oxidative stress causes PS externalization in canine erythrocytes, and NACA ameliorates this effect.

CLINICAL RELEVANCE:

Future studies are needed to determine if increased PS externalization in erythrocytes occurs in dogs with immune-mediated hemolytic anemia and its role in promoting thromboembolism.

News (Medical) associated with N-Acetylcysteine amide

02 Apr 2025

·www.prnewswire.com

Arctic Therapeutics research suggests preventative strategy against HCCAA

N-acetylcysteine (NAC) shows promise to treat hereditary cystatin C amyloid angiopathy (HCCAA) HCCAA – a subtype of cerebral amyloid angiopathy (CAA) – is an ultra-rare Icelandic amyloid disease due to a mutation in the CST3 gene encoding for the protease inhibitor, cystatin C. HCCAA causes cerebral hemorrhages in asymptomatic carriers of the L68Q variant due to amyloid aggregation with precipitation in brain vessels and tissue. Findings could guide the development of preventative therapies for related CAAs. REYKJAVIK, Iceland, April 2, 2025 /PRNewswire/ -- Icelandic drug discovery and development company Arctic Therapeutics (ATx) today announced the publication of research in JAMA Neurology, which informs a possible therapeutic strategy to treat a rare form of familial dementia. The publication, titled N-Acetylcysteine for hereditary cystatin C amyloid angiopathy (HCCAA), a nonrandomised clinical trial, details a new treatment approach for HCCAA, a rare and fatal genetic brain disorder that primarily affects young Icelandic adults, with the disease process beginning in childhood. The research provides insights into the potential of N-acetylcysteine (NAC) as a treatment for HCCAA, a disease with no currently approved therapeutic options. The study highlights how NAC may reduce disease-associated biomarkers and slow disease progression. The study is the first phase 2a clinical trial to assess the safety and therapeutic potential of high-dose NAC in patients carrying the L68Q-CST3 sequence variation of HCCAA. Results indicate that NAC is well tolerated, reduces disease specific biomarkers and stabilises disease progression, suggesting NAC may offer a preventative strategy against HCCAA. These findings could accelerate the development of preventative therapies for individuals at risk of HCCAA and other forms of CAAs. "These promising results provide hope to HCCAA patients and their families," Dr Ásbjörg Ósk Snorradóttir, lead author of the study explained. Senior author, Dr. Hákon Hákonarson, director of the Center for Applied Genomics at the Children's Hospital of Philadelphia and founder of Arctic Therapeutics added: "This study provides the first clinical evidence that NAC, by breaking disulfide bonds and other aberrant molecular interactions, can disrupt cystatin C oligomers and prevent amyloid aggregation that ultimately accumulates in brain vessels. By targeting the root biochemical process behind HCCAA pathology, NAC may ultimately offer a novel disease-modifying approach, not only for this devastating condition, but potentially for other forms of CAAs and protein aggregation disorders where toxic oligomers are central to disease progression." The open-label phase 2a clinical trial was conducted at Iceland's Landspitali University Hospital from March 2019 to December 2021. A total of 17 participants were enrolled, all confirmed carriers of the L68Q-CST3 mutation. The study assessed: Safety & tolerability: NAC was well tolerated, with no drug-related severe adverse events. Five participants experienced cerebral hemorrhages, but none resulted in permanent neurological damage. Biomarker reduction: Significant reductions were observed in collagen IV, fibronectin, vimentin, and SMAD levels—key indicators of disease progression. Plasma & skin biomarker changes: NAC was shown to increase reduced glutathione levels, a protective antioxidant, and reduce high-molecular-weight cystatin C aggregates, which are linked to amyloid buildup in the brain. Cognitive stability: No measurable decline in cognitive function was observed during the study period. Building on these findings, as well as internal in-vitro data that demonstrates that NAC-amide (NACA) has more than 10-fold higher potency in preventing or dispersing amyloid complex aggregates than NAC and increased ability to penetrate the blood brain barrier and get into cells involved in the disease pathogenesis, ATx has launched a European Medicines Agency-approved registration study to monitor safety, tolerability, and efficacy using NACA in patients with HCCAA. For more details, read the full study in JAMA Neurology: Original Investigation. About Arctic Therapeutics Arctic Therapeutics is an Icelandic drug discovery and development company established in 2015, which has licensed intellectual property from Children's Hospital of Philadelphia. ATx leverages the transformative power of applied genomics, steering the course of drug development towards safer, more effective treatments for some of the world's most challenging diseases. The company has operations in Iceland, the US and multiple collaborations across Europe. For more information, please visit: and follow us on LinkedIn For media inquires Gulli Arnason, Chief Strategy Officer [email protected] +354 660 0053 This information was brought to you by Cision The following files are available for download: WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 2Clinical Result

22 Jan 2025

·www.prnewswire.com

Arctic Therapeutics Announces €26.5M Oversubscribed Series A Financing

Funding will accelerate the company's anti-amyloid treatment for rare and common forms of dementia. As well as bringing forward a new class of treatment for inflammatory skin diseases. Sanos Group CEO Jeppe Ragnar Andersen joins the board. REYKJAVIK, Iceland and PHILADELPHIA, Jan. 22, 2025 /PRNewswire/ -- Icelandic drug discovery and development company Arctic Therapeutics (ATx) today announced the successful closing of a €26.5 million oversubscribed Series A financing from a broad syndicate of international investors. The syndicate includes the EIC Fund, Iceland's largest privately-held investment firm Kaldbakur, Investcorp-backed Sanos Group, Swiss-based Cerebrum DAO, The Lurie Family Foundation – established by US billionaire Jeffery Lurie – as well as a consortium led by early investors and co-founders of Icelandic unicorn, Kerecis, and Copenhagen-listed Chemometec. Icelandic institutional investors and family offices also participated in the round. "This funding represents a critical milestone in our journey to address significant unmet medical needs, from familial forms of dementia and Alzheimer's to novel treatments for inflammatory skin diseases. The new investors bring expertise and strategic value to the table, enabling us to accelerate the development of groundbreaking treatments," said Ivar Hakonarson, ATx co-founder and CEO. The proceeds from the Series A financing will be used to advance ATx's two frontrunners, AT-001 and AT-004, further into the clinic. Last year, the European Medicines Agency (EMA) approved a pivotal phase IIb/III clinical trial evaluating AT-001 for the treatment of Hereditary Cystatin C Amyloid Angiopathy (HCCAA), a rare form of familial dementia. The new funding will allow ATx to explore the potential of AT-001, an oral treatment designed to prevent the aggregation of harmful amyloid proteins in the brain, in other forms of familial dementia, and eventually Alzheimer's disease. "Recent advances in understanding the role of amyloid proteins and the critical importance of preventing and dissolving plaque formation in the brain underscore the transformative potential of our approach to significantly slow or even prevent these devastating diseases," Hakonarson added. In addition to the AT-001 clinical trial, ATx is also planning to launch a phase IIa clinical trial for AT-004 in Europe post-financing. The therapeutic goal of this approach is to demonstrate safety and efficacy in acne vulgaris before expanding into other inflammatory skin diseases, including atopic dermatitis, rosacea and psoriasis. Additionally, ATx announced the appointment of Jeppe Ragnar Andersen, CEO of Sanos Group, to its board of directors. "Sanos Group's proven expertise in dermatology and recent acquisition of NeuroScios, a CRO specialized in clinical studies in Alzheimer's, strengthens our alignment with ATx's therapeutic focus even further," Andersen said. "We look forward to supporting the ATx team on achieving its goal of bringing forward innovative treatments for dementia and skin diseases to millions of patients," he added. Last year, ATx was selected to join the prestigious EIC Scaling Club, an exclusive community of Europe's most promising scaleups. The Club aims to accelerate the growth of its members, with a goal of scaling 20% of them into unicorns. This aligns with the EIC Fund's investment mandate to provide funding to European companies, which have the potential to meet the world's most pressing challenges. "Investing in innovative solutions to address the global healthcare challenge of dementia is both a responsibility and an opportunity," said Svetoslava Georgieva, Chair of the EIC Fund Board. "In Europe alone, dementia affects over ten million people – placing immense strain on families, healthcare systems, and economies. By providing an equity investment in Arctic Therapeutics, the EIC Fund is supporting groundbreaking preventive treatments that have the potential to change the trajectory of this crisis, improve quality of life, and alleviate the burden on healthcare infrastructure worldwide," Georgieva added. About Arctic Therapeutics Arctic Therapeutics is an Icelandic drug discovery and development company established in 2015 as a spin-off from the US-based Center for Applied Genomics (CAG), a research center at the Children's Hospital of Philadelphia led by ATx founder Hakon Hakonarson, MD, PhD. ATx leverages the transformative power of applied genomics, steering the course of drug development towards safer, more effective treatments for some of the world's most challenging diseases. The company has operations in Iceland, the US and multiple collaborations across Europe. For more information, please visit: and follow us on LinkedIn. About Sanos Group Sanos Group is a leading specialist provider of clinical study services in the global pharma and biotech industry. The group consists of around 200 employees, mainly in Denmark and the United States, but also in Europe and Hong Kong. Last year, Sanos acquired Austrian NeuroScios, which is a contract research organization (CRO) focusing on Alzheimer's and other diseases of the central nervous system. The acquisition is part of the group's strategic development as a multi-niche CRO, adding a third specialist area to the two current scientific areas of osteoarthritis and dermatology. About EIC Fund The European Innovation Council Fund from the European Commission is an agnostic fund: it invests across all technologies and verticals, and all EU countries and countries associated to Horizon Europe. It provides the investment component of the EIC Accelerator blended finance. The European Investment Bank acts as investment adviser to the EIC Fund. The EIC Fund aims to fill a critical financing gap and its main purpose is to support companies in the development and commercialization of disruptive technologies, bridging with and crowding in market players, and further sharing risk by building a large network of capital providers and strategic partners suitable for co-investments and follow-on funding. The fund pays particular attention to the empowerment and support of female founders as well as the ambition to reduce the innovation divide among EU countries. For media inquires Gulli Arnason, Chief Strategy Officer [email protected] +354 660 0053 This information was brought to you by Cision . The following files are available for download: SOURCE Arctic Therapeutics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Executive ChangeAcquisition

21 Jan 2025

·www.globenewswire.com

Nacuity Pharmaceuticals Granted U.S. FDA Fast Track Designation for NPI-001 (N-acetylcysteine amide) Tablets for the Treatment of Retinitis Pigmentosa

FORT WORTH, Texas, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Nacuity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts and other diseases caused by oxidative stress, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to NPI-001 (N-acetylcysteine amide) tablets, Nacuity’s proprietary investigational therapy for the treatment of patients with retinitis pigmentosa (RP). A drug may receive Fast Track designation if it is intended to treat a serious or life-threatening disease and demonstrates the potential to address an unmet medical need. “Fast Track Designation represents an objective assessment by the FDA for the potential of NPI-001 tablets as a treatment for RP, a severe blinding disease,” said G. Michael Wall, Ph.D., Senior Vice President and Chief Scientific Officer of Nacuity Pharmaceuticals. “We are committed to advancing NPI-001 to address this significant unmet medical need for patients suffering from RP.” A drug that receives Fast Track designation may benefit from more frequent interactions with the FDA throughout drug development. In addition, the Fast Track program allows for Accelerated Approval and Priority Review, if relevant criteria are met. About Retinitis PigmentosaOften diagnosed in childhood or adolescence, retinitis pigmentosa (RP) is a heterogeneous group of inherited retinal diseases involving over 3,000 different mutations in more than 50 genes (Daiger et al., 2013), causing progressive night and peripheral vision loss. RP often leads to legal and sometimes complete blindness. Forms of RP and related diseases include Usher syndrome, Leber congenital amaurosis and Bardet-Biedl syndrome. An estimated 100,000 people in the U.S. have RP (https://www.fightingblindness.org/diseases/retinitis-pigmentosa). There are no FDA-approved drugs or no standard treatments for RP. A curative gene therapy, voretigene neparvovec (LUXTURNA®), exists for patients with the RPE65 mutation, about 1-6% of patients with RP (Cross et al., 2022). Nacuity researchers are working to develop a gene-agnostic treatment for RP, a significant unmet medical need. About NPI-001NPI-001 is a proprietary, GMP-grade formulation of N-acetylcysteine amide (NACA) tablets being developed to target oxidative stress associated with diseases such as retinitis pigmentosa. Preclinical studies indicate that NPI-001 boosts glutathione, the body’s most powerful endogenous antioxidant, to stop chemically aggressive oxygen molecules from damaging retinal cells. NPI-001 and related small molecules are potent antioxidants in several preclinical models that may lead to additional indications. In addition to Fast Track Designation, NPI-001 has also been granted Orphan Drug Designation for RP which provides seven years of U.S. FDA regulatory exclusivity for the product upon regulatory approval. About Nacuity Pharmaceuticals, Inc.Nacuity Pharmaceuticals is a clinical-stage leader in innovative treatments for oxidative stress. The company’s powerful, targeted therapies aim to attenuate oxidative tissue damage, a driver of blinding eye diseases and a broad spectrum of serious chronic conditions. Nacuity has three highly differentiated clinical programs ongoing for retinitis pigmentosa, cataract and cystinosis. Nacuity has operations in Fort Worth, TX, USA, and Australia, and extensive managerial and scientific domain expertise as well as backing from Foundation Fighting Blindness (https://www.fightingblindness.org/) and its venture arm RD Fund (https://www.retinaldegenerationfund.org). For more information, please visit www.nacuity.com. Trademarks are the property of their owners. Nacuity Media ContactJulia Clements267.626.1085jclements@6degreespr.com References: Cross N, van Steen C, Zegaoui Y, Satherley A, Angelillo L. Retinitis Pigmentosa: Burden of Disease and Current Unmet Needs. Clin Ophthalmol. 2022 Jun 20;16:1993-2010. doi: 10.2147/OPTH.S365486. PMID: 35757022; PMCID: PMC9232096. Daiger SP, Sullivan LS, Bowne SJ. Genes and mutations causing retinitis pigmentosa. Clin Genet. 2013 Aug;84(2):132-41. doi: 10.1111/cge.12203. Epub 2013 Jun 19. PMID: 23701314; PMCID: PMC3856531 Guidance for Industry: Expedited Programs for Serious Conditions – Drugs and Biologics, May 2014. Wood JPM, Chidlow G, Wall GM, Casson RJ. N-acetylcysteine amide and di-N-acetylcysteine amide protect retinal cells in culture via an antioxidant action. Exp Eye Res. 2024 Nov; 248:110074. doi: 10.1016/j.exer.2024.110074. Epub 2024 Sep 7. PMID: 39251120.

Orphan DrugFast TrackGene TherapyClinical Study

100 Deals associated with N-Acetylcysteine amide

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB14480

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cystinosis	Phase 2	Australia	Nacuity Pharmaceuticals, Inc.	29 Oct 2023
Usher Syndromes	Phase 2	Australia	Nacuity Pharmaceuticals, Inc.	03 Sep 2020
Alzheimer Disease	Phase 2	United States	Arctic Therapeutics	-
Cerebral Amyloid Angiopathy	Phase 2	United States	Arctic Therapeutics	-
Cerebral Amyloid Angiopathy, Familial	IND Approval	Iceland	Nacuity Pharmaceuticals, Inc.	12 Mar 2024
Cerebral Amyloid Angiopathy, Familial	IND Approval	Iceland	Arctic Therapeutics	12 Mar 2024
Brain Injuries, Traumatic	Preclinical	United States	Brighton Biotech, Inc.	15 Oct 2024
Cognition Disorders	Preclinical	United States	Brighton Biotech, Inc.	15 Oct 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00585559 (CTgov)	Phase 3	Aneurysm, Intracranial Berry, 1 \| Vasospasm, Intracranial	44	N-acetylcysteine (N-acetylcysteine IV Infusion at 0.5 gm Hourly)	spwmtcenut(wevuxzfudb) = wgjhtnpwey bxhqjhvbtm (inyiceszyl, yroxpevjwl - ygogepoakv) View more	-	18 Apr 2025
				Placebo+N-acetylcysteine (Placebo for N-acetylcysteine IV Infusion at 0.5 gm Hourly)	spwmtcenut(wevuxzfudb) = ofzgrlbjva bxhqjhvbtm (inyiceszyl, xpnikglmai - tvvxyykrkm) View more
NCT04632069 (CTgov)	Early Phase 1	Pregnancy in Diabetics \| Diabetes Mellitus \| stress oxidative	10	N acetyl cysteine + vagus nerve stimulation	opapeclfyi(ocirgcwiki) = izfbfajrwj yldmwurmfj (gokikmjyuf, 0.4) View more	-	29 Aug 2024
NCT01322009 (Pro-NAC, CTgov)	Phase 1/2	Brain Injuries, Traumatic	14	N-acetyl cysteine+Probenecid (Drug)	rfldlrtcwr = ziblsqikqk kioykbmicu (ifdvedtimy, zkxoklouas - ihkzpoyrcd) View more	-	15 Aug 2016
				Placebo (Placebo)	rfldlrtcwr = jwshtbnpnn kioykbmicu (ifdvedtimy, gmwqlhryks - pucrqovayd) View more
NCT01251315 (CTgov)	Phase 1	stress oxidative	24	Placebo (Placebo-A)	meiucxbyif(usplpsrwdx) = giwalxqwtn plonmrhxxe (ojqmdfdqhi, 133.7) View more	-	17 Mar 2014
				N Acetyl cysteine (N Acetyl Cysteine-A)	meiucxbyif(usplpsrwdx) = wwbtkkcrja plonmrhxxe (ojqmdfdqhi, 131.2) View more
NCT00332605 (CTgov)	Phase 2	Methamphetamine dependence	45	Placebo	wzlkrvsukc(hxqzurlaix) = eejamvfycy hlyzamaxhb (cfmxokfyml, 6.9) View more	-	24 Jul 2013
ARVO2008	Not Applicable	Grouped Pigmentation of the Macula	-	N-acetylcysteine amide (NACA)	igtifjxesu(zasadetkuh) = axjukleled ydscnqvpvv (uflzqxvukx )	-	01 May 2008
				N-Acetylcysteine Amide (tert-butylhydroperoxide (tBH))	igtifjxesu(zasadetkuh) = bqvmrlqosv ydscnqvpvv (uflzqxvukx )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis